289 patents
Page 12 of 15
Utility
Animal and human anti-malarial agents
10 Aug 20
Stacie S. Canan, Natalie Anne Hawryluk
Filed: 13 Aug 19
Utility
4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors
3 Aug 20
Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett
Filed: 5 Dec 18
Utility
Compositions and Methods of Use of CIS-4-[2-{[(3S,4R)-3-FLUOROOXAN-4-YL]AMINO}-8-(2,4,6-TRICHLOROANILINO)-9H-PURIN-9-YL]-1-METHYLCYCLOHEXANE-1-CARBOXAMIDE
29 Jul 20
Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
Filed: 9 Apr 20
Utility
Methods of Using SMAD7 Antisense Oligonucleotides Based on Biomarker Expression
29 Jul 20
Described herein are methods of treating inflammatory bowel disease (IBD) in a patient having IBD using SMAD7 antisense oligonucleotides.
Salvatore BELLINVIA, Giovanni MONTELEONE, Gerald Scott BARDEN HORAN
Filed: 29 Sep 16
Utility
Formulations of 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE
29 Jul 20
Provided herein are lyophilized formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereisomer or mixture of stereisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
Ho-Wah Hui, Yu Pu
Filed: 8 Sep 19
Utility
Polymorphic Forms of 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE
29 Jul 20
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed.
Markian S. Jaworsky, Roger Shen-Chu Chen, George W. Muller
Filed: 1 Mar 20
Utility
Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same
22 Jul 20
Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof.
Hon-Wah Man, Roger Shen-Chu Chen, George W. Muller, Alexander L. Ruchelman, Ehab M. Khalil, Weihong Zhang
Filed: 30 Mar 20
Utility
Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate
20 Jul 20
Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof.
John F. Traverse, Michael J. Zacuto, Weihong Zhang, Kirsten Faye Johnson, Maryll E. Geherty, Christopher Marton
Filed: 19 Aug 18
Utility
Formulations of 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE
15 Jul 20
Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein.
Anthony J. Tutino, Michael T. Kelly
Filed: 15 Jan 20
Utility
Solid Forms Comprising (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE and Salts Thereof, and Compositions Comprising and Methods of Using the Same
8 Jul 20
Provided herein are formulations, processes, solid forms and methods of use relating to salts of and solid forms comprising free base or salts of (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile.
Gerald D. Artman, III, Antonio C. Ferretti, Lianfeng Huang, Udaykumar Jain, Hon-Wah Man, Paul A. Tavares-Greco, Wenju Wu
Filed: 7 Jan 20
Utility
Pharmaceutical Compositions Comprising (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE and Methods of Using the Same
8 Jul 20
Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent.
Anjali Agrawal, Ming J. Chen, Shyam Babu Karki, Prajwal Gunwanth Thool, Dora Visky, Ruimin Xie
Filed: 7 Jan 20
Utility
Antiproliferative Compounds and Second Active Agents for Combined Use
8 Jul 20
Provided herein are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing multiple myeloma.
Lilly L. Wong
Filed: 7 Jan 20
Utility
Compositions and Methods of Use of 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE
1 Jul 20
Provided herein are formulations and methods of use of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, isotopologue, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
Rowena Fernandez Choudrie, Willard Foss, Che-Hsiung Hsu, Amol Mungikar, Yu Pu
Filed: 29 Dec 19
Utility
Combination therapy for treating malignancies
29 Jun 20
Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
Vivek Saroj Kumar Chopra, Jorge DiMartino, Laurie A. Kenvin, Robert Douglas Knight, Kyle MacBeth, Krishnan Viswanadhan, Qiang Xu, Samuel V. Agresta
Filed: 13 Oct 16
Utility
Substituted 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE Compounds, Compositions Thereof, and Methods of Treatment Therewith
24 Jun 20
Massimo Ammirante, Sogole Bahmanyar, Matthew D. Correa, Virginia Grant, Joshua Hansen, Evan J. Horn, Timothy S. Kercher, Christopher Mayne, Mark A. Nagy, Rama Krishna Narla, Surendra Nayak, Stephen Norris, Patrick Papa, Veronique Plantevin-Krenitsky, John J. Sapienza, Brandon W. Whitefield, Shuichan Xu
Filed: 17 Dec 19
Utility
Substituted 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE Compounds, Compositions Thereof, and Methods of Treatment Therewith
24 Jun 20
Massimo Ammirante, Sogole Bahmanyar, Matthew D. Correa, Virginia Grant, Joshua Hansen, Evan J. Horn, Timothy S. Kercher, Christopher Mayne, Mark A. Nagy, Rama Krishna Narla, Surendra Nayak, Stephen Norris, Patrick Papa, Veronique Plantevin-Krenitsky, John J. Sapienza, Brandon W. Whitefield, Shuichan Xu
Filed: 17 Dec 19
Utility
Thienopyridine Inhibitors of RIPK2
24 Jun 20
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Kurt Armbrust, Fedor Romanov Michailidis, Karin Irmgard Worm, John Michael Ellis
Filed: 19 Dec 19
Utility
Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
22 Jun 20
In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers that correlate with responsiveness to one of these drugs.
Matthew William Burnell Trotter, Alberto Risueno Perez, Michael Pourdehnad, Anita Gandhi, Patrick Hagner
Filed: 21 Sep 16
Utility
PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
15 Jun 20
Methods of treating immune reconstitution inflammatory syndrome (IRIS) in immunodeficient patients, including HIV patients, using PDE4 modulators are described.
Vikram Khetani, Jerome Zeldis
Filed: 19 Oct 16
Utility
Antiproliferative compounds and methods of use thereof
8 Jun 20
Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds.
Matthew D. Alexander, Gerald D. Artman, III, Matthew D. Correa, Joshua Hansen, Xiaoling Lu, Hon-Wah Man, Mark A. Nagy, Paula A. Tavares-Greco, Brandon W. Whitefield, Nanfei Zou
Filed: 2 Jun 19